Thus, the combination of MPC1/2 inhibition with standard-of-care drug imatinib causes a significant reduction in therapy resistant CD34+CD38− CML cells at clinically administrable doses in vivo. The gene discussed is CD38; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.